C2 and cancer: In Myeloid cells, 12.12% of cancers had significantly better OS predicted by the 475 scSTAR-C3 marker genes upregulated after ATHENA treatment, while 21.65% of cancers had significantly better OS predicted by the 163 scSTAR-C2 marker genes downregulated after ATHENA treatment.